|
Prof Timothy Hughes speaks to ecancer.tv about the ENESTnd trial which is evaluating the efficacy and safety of the second generation tyrosine kinase inhibitor nilotinib in newly diagnosed chronic myeloid leukaemia (CML) patients. This study compared standard imatinib treatment with nilotinib 300mg twice daily or nilotinib 400mg twice daily and found that both nilotinib regimens had superior efficacy over imatinib with significantly higher rates of major molecular response, complete cytogenetic response and significantly lower rates of progression to accelerated phase / blast phase. Prof Hughes discusses the differences in toxicity between the two agents and between the two nilotinib regimens, considers the benefits of putting patient straight onto nilotinib as first line treatment and talks about CML becoming a truly chronic manageable disease.
|
Video Length: 0
Date Found: February 18, 2011
Date Produced:
|
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured Content
Featuring websites that enhance the internet user’s experience.
|